CARL GRAY, M.D.
Hematology & Oncology Physician · OGDEN, UT
Individual Active NPI 1598873382
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 373 | 512,033 | $21,375,061 | $12,148,950 | $9,682,167 |
| 2023 | 398 | 424,418 | $16,938,762 | $9,453,203 | $7,529,815 |
| 2022 | 863 | 508,085 | $21,073,179 | $10,264,738 | $8,167,588 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | 71,260 | $31 | $25 |
| J0185 | Injection, aprepitant, 1 mg | 45,890 | $2 | $1 |
| J9271 | Injection, pembrolizumab, 1 mg | 27,000 | $56 | $45 |
| J1071 | Injection, testosterone cypionate, 1 mg | 22,400 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 21,540 | $25 | $20 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 19,440 | $49 | $39 |
| Q5125 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | 19,200 | $0 | $0 |
| J1627 | Injection, granisetron, extended-release, 0.1 mg | 14,500 | $6 | $4 |
| Q5126 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | 12,763 | $58 | $46 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 11,582 | $0 | $0 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 2,760 | $1 | $1 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 2,053 | $4 | $4 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | 5553369-1205 | UT |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Utah
- NPI 1295976827
- NPI 1972922938
- NPI 1326156191
- NPI 1770098204
- NPI 1114362001
- NPI 1093245607
- NPI 1427273705
- NPI 1316354780
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.